Risk of Cardiovascular Disease in Patients With MS Treated With Fingolimod vs Natalizumab
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Risk of cardiovascular disease in patients with multiple sclerosis treated with fingolimod compared to natalizumab: A nationwide cohort study of 2095 patients in Denmark
Mult. Scler. 2024 Jan 11;[EPub Ahead of Print], E Framke, LC Thygesen, M Malmborg, M Schou, F Sellebjerg, M MagyariFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.